Valproic acid drug delivery systems and intraocular therapeutic uses thereof
AssigneeAllergan, Inc.
InventorsWendy M. Blanda, Patrick M. Hughes, Peter C. Baciu
Life of this patent
Estimating the term…
Abstract
Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.
Claims9
A method for treating a retinal condition, the method comprising the step of intraocular administration to a patient with a retinal condition of a drug delivery system comprising a bioerodible polymer and a valproic acid associated with the bioerodible polymer.
A method for treating a macular edema, the method comprising the step of intravitreal administration to a patient with macular edema of a drug delivery system comprising a bioerodible polymer and a valproic acid associated with the bioerodible polymer.
A method for reducing retinal tissue oxidative stress in a human patient, the method comprising the step of intravitreal administration to a human patient with oxidative stress retinal cells of a drug delivery system comprising a bioerodible polymer and a valproic acid associated with the bioerodible polymer.
Dependencies are inferred from the claim text.